Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial

Open access
Bosch, Jackie, Eikelboom, John W., Connolly, Stuart J., Bruns, Nancy Cook, Lanius, Vivian, Yuan, Fei, Misselwitz, Frank, Chen, Edmond, Diaz, Rafael, Alings, Marco, Lonn, Eva M., Widimsky, Petr, Hori, Masatsugu, Avezum, Alvaro, Piegas, Leopoldo S., Bhatt, Deepak L., Branch, Kelley R.H., Probstfield, Jeffrey L., Liang, Yan, Liu, Lisheng, Zhu, Jun, Maggioni, Aldo P., Lopez-Jaramillo, Patricio, O'Donnell, Martin, Fox, Keith A.A., Kakkar, Ajay, Parkhomenko, Alexander N., Ertl, Georg, Störk, Stefan, Keltai, Katalin, Keltai, Matyas, Ryden, Lars, Dagenais, Gilles R., Pogosova, Nana, Dans, Antonio L., Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomasz J., Verhamme, Peter B., Vinereanu, Dragos, Kim, Jae-Hyung, Ha, Jong-Won, Tonkin, Andrew M., Varigos, John D., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Steg, Philippe Gabriel, Aboyans, Victor, Metsarinne, Kaj P., Anand, Sonia S., Hart, Robert G., Lamy, Andre, Moayyedi, Paul, Leong, Darryl P., Sharma, Mukul, Yusuf, Salim · 2017 · Canadian Journal of Cardiology

Abstract

BACKGROUND: Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alone or in combination with aspirin might be more effective than aspirin alone for vascular prevention in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD). Rivaroxaban as well as aspirin increase upper gastrointestinal (GI) bleeding and this might be prevented by proton pump inhibitor therapy. METHODS: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) is a double-blind superiority trial comparing rivaroxaban 2.5 mg twice daily combined with aspirin 100 mg once daily or rivaroxaban 5 mg twice daily vs aspirin 100 mg once daily for prevention of myocardial infarction, stroke, or cardiovascular death in patients with stable CAD or PAD. Patients not taking a proton pump inhibitor were also randomized, using a partial factorial design, to pantoprazole 40 mg once daily or placebo. The trial was designed to have at least 90% power to detect a 20% reduction in each of the rivaroxaban treatment arms compared with aspirin and to detect a 50% reduction in upper GI complications with pantoprazole compared with placebo. RESULTS: Between February 2013 and May 2016, we recruited 27,395 participants from 602 centres in 33 countries; 17,598 participants were included in the pantoprazole vs placebo comparison. At baseline, the mean age was 68.2 years, 22.0% were female, 90.6% had CAD, and 27.3% had PAD. CONCLUSIONS: COMPASS will provide information on the efficacy and safety of rivaroxaban, alone or in combination with aspirin, in the long-term management of patients with stable CAD or PAD, and on the efficacy and safety of pantoprazole in preventing upper GI complications in patients receiving antithrombotic therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cjca.2017.06.001

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 161

Metadata

Authors
Bosch, J., Eikelboom, J. W., Connolly, S. J., Bruns, N. C., Lanius, V., Yuan, F., Misselwitz, F., Chen, E., Diaz, R., Alings, M., Lonn, E. M., Widimsky, P., Hori, M., Avezum, A., Piegas, L. S., Bhatt, D. L., Branch, K. R. H., Probstfield, J. L., Liang, Y., Liu, L., Zhu, J., Maggioni, A. P., Lopez-Jaramillo, P., O'Donnell, M., Fox, K. A. A., Kakkar, A., Parkhomenko, A. N., Ertl, G., Störk, S., Keltai, K., Keltai, M., Ryden, L., Dagenais, G. R., Pogosova, N., Dans, A. L., Lanas, F., Commerford, P. J., Torp-Pedersen, C., Guzik, T. J., Verhamme, P. B., Vinereanu, D., Kim, J.-H., Ha, J.-W., Tonkin, A. M., Varigos, J. D., Lewis, B. S., Felix, C., Yusoff, K., Steg, P. G., Aboyans, V., Metsarinne, K. P., Anand, S. S., Hart, R. G., Lamy, A., Moayyedi, P., Leong, D. P., Sharma, M., & Yusuf, S.
Venue
Canadian Journal of Cardiology
Publisher
Elsevier BV
Published
2017-08
Volume
33
Issue
8
Pages
1027-1035
ISSN
0828-282X (ISSN-L)
OpenAlex
W2621785677
Cited by
161
References
9
FWCI
17.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.